Project Grant R44AI184225
Award Date
12/20/24
Completion Date
11/30/26
Dollars Obligated
$1M
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Morrisville, NC, USA
Similar Awards
This Cooperative Agreement award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $297,917 in funding to Trellis Bioscience, Inc. to conduct a Phase 1 safety trial for their TRL1068 therapeutic antibody, which is formulated for nebulized delivery as an inhaled treatment for bronchial infections.
The TRL1068 antibody has previously demonstrated efficacy in disrupting bacterial biofilms and enhancing the...
The National Institute of Allergy and Infectious Diseases (NIAID) has awarded a $868,776 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Children's Hospital Corporation (Boston Children's Hospital). The grant is to fund a 5-year project from February 2025 to January 2030 to characterize a novel post-transcriptional regulator in the opportunistic pathogen Pseudomonas aeruginosa. Key objectives include identifying the direct regulatory targets of...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $300,000 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Via Therapeutics, LLC, a for-profit limited liability company in Austin, Texas. The purpose of this 11-month grant is to develop a stable, aerosolizable dry powder formulation of bacteriophages (D29 phages) encapsulated in polymeric microparticles for the treatment of pulmonary tuberculosis (TB) infections. The key...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) to Scientific Horizons Consulting LLC will support research into a novel antibiotic delivery system using cyclodextrin-based metal-organic frameworks (CD-MOFs) to treat non-tuberculous mycobacterial (NTM) lung infections. The $298,530 award, effective July 1, 2024 through June 30, 2025, will fund the development and evaluation of antibiotic/CD-MOF...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research to understand the interactions between the opportunistic pathogens Pseudomonas aeruginosa and Mycobacterium abscessus, and identify novel antimicrobial strategies to treat biofilm-associated infections. The project, titled "Surface Dependent Inhibition of Mycobacterium Abscessus by Pseudomonas Aeruginosa", will utilize...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to CFD Research Corporation to develop a novel class of antibiotics for treating drug-resistant gonorrhea. The $291,697 award, with a project period from April 18, 2024 to March 31, 2026, seeks to optimize a promising natural product compound discovered by CFD Research for improved potency, safety, and drug-like properties. The...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $299,995 to Xiretsa Inc. to develop a novel class of membrane-modifying antimicrobial agents called Anti-infective Conjugated Electrolytes (ACEs). The goal is to identify promising ACE lead compounds that can act as life-saving treatments for critical gram-negative bacterial infections, particularly those caused by Klebsiella pneumoniae. The...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Trustees of the Colorado School of Mines. The award, totaling $384,554, aims to develop novel drug candidates that target the SUF-like pathway of iron-sulfur cluster biosynthesis as a treatment for drug-resistant infections caused by Gram-positive bacteria such as Staphylococcus aureus, Enterococcus faecalis, and...
This federal Project Grant award of $750,815, provided by the National Institute of Allergy and Infectious Diseases (CFDA 93.855 Allergy and Infectious Diseases Research), supports research to develop novel anti-infective strategies for treating pulmonary mucormycosis, a deadly invasive fungal infection.
The project aims to examine the role of the host cell hypoxia-response pathway in mucormycosis pathogenesis and explore the therapeutic potential of targeting key downstream effectors like...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $522,827 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Vanderbilt University Medical Center (VUMC) to conduct research on Pseudomonas pathogenesis in the bladder. The primary objectives are to elucidate how the uropathogen Pseudomonas aeruginosa establishes acute infection and to determine whether age influences infection establishment and persistence. Specifically, the...